Revenue segments as reported by the company.

Proprietary Products

Contract - Manufactured Products

Eliminations

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Selling, general and administrative

Other (income) expense

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

West Pharmaceutical Services

West Pharmaceutical Services, Inc. manufactures and markets pharmaceuticals, biologics, vaccines and consumer healthcare products. It operates through the following business segments: Proprietary Products and Contract-Manufactured Products. The Proprietary Products segment offers proprietary packaging, containment and drug delivery products, along with analytical lab services, to biologic, generic and pharmaceutical drug customers. The Contract-Manufactured Products segment serves as a fully integrated business, focused on the design, manufacture and automated assembly of complex devices, primarily for pharmaceutical, diagnostic, and medical device customers. The company was founded by Herman O. West on July 27, 1923 and is headquartered in Exton, PA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

West Pharmaceutical Services reports solid growth and strategic investments

West Pharmaceutical Services showed resilience with 8% organic sales growth in 2022 despite challenges.
2023 guidance includes growth projections, margin expansion, and a share repurchase program.
The company's pricing strategy and investments in high-value products position it for future success.
Despite COVID impacts, West remains focused on growth opportunities and sustainability efforts.

West Pharmaceutical Services reports solid Q1 performance and growth outlook

West Pharmaceutical Services (WST) showcased strong Q1 performance with growth in key market units and ongoing investments in capacity expansion.
Despite challenges such as declining profitability metrics and inflationary pressures, the company remains optimistic about its full-year outlook and growth prospects.
Opportunities lie in sustained growth in Contract Manufacturing, revenue diversification, and a focus on margin expansion to drive future financial success.
Analysts' inquiries highlighted areas for improvement, signaling a proactive approach to addressing challenges and capitalizing on growth opportunities.

West Pharmaceutical Services excels in Q2, eyes growth opportunities

West Pharmaceutical Services reported strong Q2 performance driven by key business units and growth drivers, with a focus on sustainability and capacity investments. Despite challenges like margin expectations and external events, the company remains well-positioned for growth. Opportunities lie in revenue pickup in Q4, strategic partnerships, and global market expansion.

West Pharmaceutical Services reports solid Q3 performance and eyes growth through automation and strategic investments

West Pharmaceutical Services delivered solid Q3 performance with growth in net sales and adjusted EPS, despite challenges in inventory management and capacity constraints.
The company's strategic investments in automation and capacity expansions position it well for future growth opportunities in HVP and biologics.
While facing industry challenges and uncertainties, West remains confident in meeting or exceeding its growth targets for 2024 through continuous monitoring and adjustment.
Maintaining a strong focus on customer commitments and market differentiation, West Pharmaceutical Services aims to drive growth through innovation and operational efficiency.

West Pharmaceutical Services reports solid Q4 results amidst 2024 challenges

West Pharmaceutical Services navigated challenges in Q4 2023 with solid performance and a focus on growth drivers for 2025, despite anticipated hurdles in 2024.
The company's strategic approach to capital allocation, market share strength, and product focus position it well for future growth and resilience.
Balancing challenges with opportunities, West Pharmaceutical Services aims to sustain growth momentum, overcome obstacles, and drive efficiency and innovation.
With a strong order book outlook, normalized margin rates, and a focus on market trends, West Pharmaceutical Services is poised for continued success and market leadership.

West Pharmaceutical Services navigates mixed Q1 performance with strategic resilience

West Pharmaceutical Services faced challenges in Q1 2024 but demonstrated strengths in strategic planning and resilience.
The company's focus on capacity expansions and maintaining guidance reflects a commitment to long-term growth.
Addressing challenges related to customer destocking and financial performance will be crucial for seizing opportunities and enhancing competitiveness.

West Pharmaceutical Services faces Q2 challenges but eyes future growth

West Pharmaceutical Services navigated challenges in Q2 2024 due to customer destocking, impacting organic sales and gross profit margin. Despite this, management remains optimistic about future growth prospects, aiming to return to a 7% to 9% growth construct. Adjusted full-year guidance reflects a more gradual recovery, with a focus on strategic investments for future growth.

West Pharmaceutical Services reports solid Q3 results amid margin challenges

West Pharmaceutical Services reported solid Q3 performance but faced declines in key financial metrics compared to the previous year. The company is focusing on leveraging its strengths in biologics and expertise to drive future growth, while addressing challenges in margins and organic sales. Opportunities lie in improving performance in Q4 and capitalizing on increased guidance for net sales and adjusted EPS.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Gilead Sciences

Haleon PLC

Medtronic

Merck

Novartis

Zimmer Biomet Hlds

One of my favorite sectors will always be the healthcare sector. It is practically a basic need for all human beings and is always in constant development and growth.

7 Healthcare Stocks to invest in for a Healthy Future

West Pharmaceutical (WST) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Analysts Estimate West Pharmaceutical Services (WST) to Report a Decline in Earnings: What to Look Out for

West Pharmaceutical Services, Inc. has experienced a 60% gain in its stock price so far in 2023 but has hit some recent technical headwinds. Insiders have also sold a significant number of shares in August and September, and the stock's free cash flow yield is dwarfed to what is available in short-term treasuries. The stock also seems stretched based on its current P/E and price-to-sales valuation metrics.

West Pharmaceutical Services: The Run Might Be Over

Expert presentations and posters offer thought leadership in drug delivery innovation, patient adherence and pharmaceutical manufacturing  EXTON, Pa. , Oct. 16, 2023 /PRNewswire/ --  West Pharmaceutical Services, Inc. (NYSE: WST), a global leader in innovative solutions for injectable drug administration, today announced participation in the 2023 PDA Universe of Pre-Filled Syringes and Injection Devices Conference in Gothenburg, Sweden to showcase its leadership and expertise on industry challenges and trends in packaging and containment.

West to Present on Development of Large Volume Delivery Systems, Self-injection Devices, and Prefillable Syringe Component Expertise at the PDA Conference

EXTON, Pa. , Oct. 12, 2023 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE: WST), a global leader in innovative solutions for injectable drug administration, today announced that it will release third-quarter 2023 financial results before the market opens on Thursday, October 26, 2023, and will follow with a conference call to discuss the results and business expectations at 9:00 a.m. Eastern Time.

West to Host Third-Quarter 2023 Conference Call

Arista Networks

Booking Hlds

Cadence Design Systems

Alphabet

Eli Lilly

Palo Alto Networks

Synopsys

SPDR S&P 500 ETF Trust

Risk and reward are supposed to be attached at the hip for S&P 500 stocks. But a small group of stocks are delivering all gain and no pain.

9 'Unstoppable' Stocks Deliver Big Gains And No Pain To Investors

Align Technology

Henry Schein

McKesson

Here we discuss four stocks from the Dental Supplies industry that are likely to earn wealth for investors. These include MCK, WST, ALGN and HSIC.

4 Stocks to Buy From the Prospering Dental Supplies Industry

Airbnb

Amazon

Carnival

Salesforce

General Electric

NVIDIA

PulteGroup

Royal Caribbean Cruises

Tesla

The S&P 500 is up 12.5% so far in 2023, even with the market correction. But an equal-weight ETF is up just 1%.

These Are The 12 Stocks Driving The S&P 500 Higher In 2023

Corning

Although these companies are from different sectors, we compare them because they have a similar market capitalization of around $30 billion.

Which Is A Better Pick – Corning Stock Or West Pharmaceutical Services?

DexCom

DexCom, Eli Lilly, and West Pharmaceutical Services have been among the hottest healthcare stocks to own over the past decade. These top healthcare companies are in good positions to benefit from even more growth in the future.

3 Healthcare Stocks That Turned $100,000 Into $1 Million in 10 Years

Caterpillar

Emerson Electric

Building a well-rounded portfolio is crucial as you plan for financial stability in your retirement. Diversification is critical, ensuring your investments are spread across various sectors and asset types.

The 3 Best Retirement Stocks to Buy Now: September 2023

West Pharmaceutical's (WST) strength in its proprietary products segment raises optimism about the stock.

Reasons to Retain West Pharmaceutical (WST) Stock for Now

West Pharmaceutical (WST) continues to gain momentum due to its strength in the Proprietary Products business. However, forex concerns persist.

West Pharmaceutical (WST) Hits 52-Week High: More Room to Grow?

IQVIA Hlds

Regeneron Pharmaceuticals

Vertex Pharmaceuticals

Zoetis

For investors, tracking the stocks that are up in what has otherwise been a grim year for drugmakers can help identify trends in the market.

In a Tough Year for Pharma, These 6 Stocks Are Shining

West Pharmaceutical Services has seen a 60% rally in its stock price since December 2022, outperforming the S&P 500. Momentum in financials shows a decline in top line sales but strong growth in contract-manufactured revenues and free cash flow. The company has demonstrated the ability to compound value for shareholders and has attractive technical indicators for future growth.

West Pharmaceutical: Revise To Buy On Exceptional Economic Characteristics

West Pharmaceutical Services, Inc. (NYSE:WST ) Q2 2023 Earnings Conference Call July 27, 2023 9:00 AM ET Company Participants Barbara Tuckfield - Director of Investor Relations Gerry Norcia - Chairman and Chief Executive Officer Dave Ruud - Executive Vice President & Chief Financial Officer Conference Call Participants Jeremy Tonet - JPMorgan Shahr Pourreza - Guggenheim Heidi Hauchon - Bank of America Michael Sullivan - Wolfe Research David Arcaro - Morgan Stanley Alex Mortimer - Mizuho Operator Good morning, ladies and gentlemen. Welcome to the DTE Energy Second Quarter 2023 Earnings Conference Call.

West Pharmaceutical Services, Inc. (WST) Q2 2023 Earnings Call Transcript

West Pharmaceutical's (WST) second-quarter results reflect a sustained recovery in non-COVID-19 demand amid dismal overall performance.

West Pharmaceutical (WST) Q2 Earnings Beat, HVP Drives Sales

Although the revenue and EPS for West Pharmaceutical (WST) give a sense of how its business performed in the quarter ended June 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

West Pharmaceutical (WST) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates

West Pharmaceutical Services (WST) came out with quarterly earnings of $2.11 per share, beating the Zacks Consensus Estimate of $1.95 per share. This compares to earnings of $2.47 per share a year ago.

West Pharmaceutical Services (WST) Tops Q2 Earnings and Revenue Estimates

- Conference Call Scheduled for 9 a.m. EDT Today - EXTON, Pa.

West Announces Second-Quarter 2023 Results

Roper Technologies

T. Rowe Price Group

The stock market has been on an absolute tear this year with the S&P 500 up 19% and the Nasdaq 100 up a whopping 42.6% YTD.

Worried About Market Froth? Buy These 3 Dividend Stocks

Applied Materials

CRH PLC

FedEx

KLA-Tencor

Lam Research

Monolithic Power Systems

NetEase

Schwab US Dividend Equity ETF

Taiwan Semiconductor Manufacturing

My portfolio based on the stock selection methodology of The Dow Jones US Dividend 100 Index has returned 21.72% since its inception 8.5 months ago. This deep dive analysis tested the contribution that each of the 4 factors played on the final return of the portfolio. I performed simple linear regression analysis and single and multi-factor analysis which generated surprising results.

4 Factor Dividend Growth Portfolio - Deep Dive Analysis

West Pharmaceutical (WST) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

West Pharmaceutical Services (WST) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

Reasons to Add West Pharmaceutical (WST) to Your Portfolio Now

Cooper Companies

Patterson Companies

DENTSPLY SIRONA

Here we discuss five stocks from the Dental Supplies industry that are likely to create wealth for investors. These include WST, ALGN, COO, XRAY and PDCO.

5 Stocks to Buy From the Prospering Dental Supplies Industry

News for West Pharmaceutical Services Stock (WST)